Item 7.01 Regulation FD Disclosure.

On January 10, 2020, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its preliminary unaudited full year 2019 total revenues and providing initial full year 2020 guidance. A copy of such press release and the attached financial schedules are attached as Exhibit 99.1 to this report and incorporated into this Item 2.02 by reference.

The information in this Current Report on Form 8-K under Items 2.02 and 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits





(d) Exhibits.

Exhibit Number   Description

  99.1           Press Release, dated January 10, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses